His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Ser Lys Lys Lys Lys Lys Lys
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BJ Glucagon-like peptide-1 (GLP-1) analogues
A10BJ03 Lixisenatide
D09729 Lixisenatide (JAN/USAN/INN) <JP>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
GLP-1 Receptor Agonist
Lixisenatide
D09729 Lixisenatide (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
24 Hormones
249 Miscellaneous
2499 Others
D09729 Lixisenatide (JAN/USAN/INN)
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01493 GLP-1 receptor agonist
D09729 Lixisenatide
Drug classes [BR:br08332]
Antidiabetic agent
DG01493 GLP-1 receptor agonist
D09729 Lixisenatide
DG02044 Hypoglycemic agent
D09729 Lixisenatide
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Secretin receptor family
Glucagon
GLP1R
D09729 Lixisenatide (JAN/USAN/INN) <JP>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09729
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09729
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09729
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09729